Eli Lilly invests $1.3 billion in Verve Therapeutics to develop one-time cardiovascular gene therapy
TL;DR
Verve Therapeutics' stock nearly doubled after Eli Lilly announced a $1.3 billion takeover, boosting gene-editing stocks. Lilly's acquisition includes a $10.50 per share offer plus a contingent value right, reflecting confidence in Verve's gene-editing treatments for cardiovascular diseases, despite some safety concerns in earlier trials. The deal is seen as a win for Verve shareholders and highlights Lilly's strategic interest in gene therapy for heart conditions.
- Eli Lilly Gets Into The Gene-Editing Space With $1 Billion Takeout Investor's Business Daily
- Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk Eli Lilly and Company
- This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly MarketWatch
- Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say Yahoo Finance
- Verve Therapeutics Stock Soars 77% After Eli Lilly’s $1.3 Billion Bid Barron's
Want the full story? Read the original reporting
Read on Investor's Business Daily